Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
January 16, 2023 Cover
Volume 101, Issue 2
We analyze the business trends, government policies, and societal forces that will affect chemistry in the year ahead
Cover image:We analyze the business trends, government policies, and societal forces that will affect chemistry in the year ahead.
Credit: Shutterstock
C&EN’s World Chemical Outlook 2023
We analyze the business trends, government policies, and societal forces that will affect chemistry in the year ahead
J.P. Morgan Healthcare Conference returns to San Francisco
Rare disease M&A’s, on-site enthusiasm mark 2023 meeting
Combination method peers into tissues to study early disease processes
Researchers combine tissue clearing with proteomics
-
US Chemical Safety Board issues delayed accident reports
CSB also identifies hundreds of serious incidents in the last 2.5 years
-
FDA green-lights lecanemab to treat Alzheimer’s disease
The developers list an annual price of $26,500 per patient
-
Fireproof polymer electrolyte for high-performance batteries
Adding extra salt to a rubbery polymer creates a safer electrolyte for lithium-ion batteries
ADVERTISEMENT
J.P. Morgan Healthcare Conference returns to San Francisco
Rare disease M&A’s, on-site enthusiasm mark 2023 meeting
Business & Policy Concentrates
- FDA green-lights lecanemab to treat Alzheimer’s disease
- Capsida teams up with Lilly subsidiary for gene therapies
- US EPA proposes tighter limits on fine particulate matter air pollution
- EPA affirms ethylene oxide’s health hazards
- Viking Therapeutics accuses competitor of pilfering proprietary information
